VK2809
VK2809-201
Phase 2 small_molecule completed
Quick answer
VK2809 for Hyperlipidemia is a Phase 2 program (small_molecule) at Viking Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Viking Therapeutics
- Indication
- Hyperlipidemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed